As continued work with berzosertib ensues, it will be important to consider biomarker-driven approaches that target tumours harbouring ATM truncating mutations or ATM protein loss, TP53 mutations, BRCA1 or BRCA2 mutations, or other alterations conferring homologous recombination repair deficiency. This evidence concerns the gene BRCA1 and neoplasm.